Ameritas Investment Partners’s BioXcel Therapeutics BTAI Stock Holding History

Ameritas Investment Partners’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-84	Closed	-$3.81K	–	3140
2024 Q1	$3.81K	Hold	84	–	–	﹤0.01%	2982
2023 Q4	$3.98K	Hold	84	–	–	﹤0.01%	3006
2023 Q3	$3.42K	Hold	84	–	–	﹤0.01%	3031
2023 Q2	$8.99K	Hold	84	–	–	﹤0.01%	2941
2023 Q1	$25.2K	Hold	84	–	–	﹤0.01%	2366
2022 Q4	$41.8K	Hold	84	–	–	﹤0.01%	2185
2022 Q3	$15K	Hold	84	–	–	﹤0.01%	2640
2022 Q2	$17K	Hold	84	–	–	﹤0.01%	2621
2022 Q1	$28K	Hold	84	–	–	﹤0.01%	2398
2021 Q4	$27K	Buy	84 +16	+24%	+$6.87K	﹤0.01%	2491
2021 Q3	$33K	Hold	68	–	–	﹤0.01%	2410
2021 Q2	$31K	Hold	68	–	–	﹤0.01%	2477
2021 Q1	$47K	Buy	68 +10	+17%	+$8.04K	﹤0.01%	2117
2020 Q4	$43K	Hold	58	–	–	﹤0.01%	2071
2020 Q3	$41K	Hold	58	–	–	﹤0.01%	1952
2020 Q2	$50K	Buy	58 +25	+76%	+$16.3K	﹤0.01%	1814
2020 Q1	$12K	Hold	33	–	–	﹤0.01%	2433
2019 Q4	$8K	Hold	33	–	–	﹤0.01%	2797
2019 Q3	$4K	Hold	33	–	–	﹤0.01%	2955
2019 Q2	$6K	Buy	+33	New	+$5.59K	﹤0.01%	2912

Other funds holding BTAI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ameritas Investment Partners's BTAI Position: Q2 2024 in Review

Ameritas Investment Partners sold out of BioXcel Therapeutics (BTAI) in Q2 2024, closing a stake of 84 shares — an estimated $3.81K sold.

Ameritas Investment Partners first reported a position in BTAI in Q2 2019 and held it in 20 quarters. The position peaked at $50K in Q2 2020. 74 funds tracked by Wall St. Rank hold BTAI as of Q2 2024.

Ameritas Investment Partners reported no remaining BioXcel Therapeutics position as of Q2 2024 after selling out during the quarter.
Ameritas Investment Partners sold 84 BioXcel Therapeutics shares in Q2 2024, an estimated $3.81K.
Ameritas Investment Partners first reported a position in BioXcel Therapeutics in Q2 2019 and held it in 20 quarters.
Ameritas Investment Partners's BioXcel Therapeutics position peaked at $50K in Q2 2020.
74 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2024.

Based on Ameritas Investment Partners's 13F filing for Q2 2024, filed 13 Aug 2024.